141 related articles for article (PubMed ID: 17534162)
1. Defining the role of immunotherapy and radioimmunotherapy in the treatment of low-grade lymphoma.
Winter JN
Curr Opin Hematol; 2007 Jul; 14(4):360-8. PubMed ID: 17534162
[TBL] [Abstract][Full Text] [Related]
2. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
4. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
5. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
Vose J
Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.
Maloney DG
J Clin Oncol; 2005 Sep; 23(26):6421-8. PubMed ID: 16155029
[TBL] [Abstract][Full Text] [Related]
7. Current controversies in follicular lymphoma.
Aurora V; Winter JN
Blood Rev; 2006 Jul; 20(4):179-200. PubMed ID: 16410034
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatments for indolent lymphoma.
Cheson BD; Gregory SA; Marcus R
Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
[TBL] [Abstract][Full Text] [Related]
9. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
Vose JM
Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
[TBL] [Abstract][Full Text] [Related]
10. [Radio-immunotherapy for B-cell non-Hodgkin lymphoma].
Visser OJ; Zijlstra JM; van Dongen GA; Huijgens PC
Ned Tijdschr Geneeskd; 2005 Oct; 149(42):2324-8. PubMed ID: 16261710
[TBL] [Abstract][Full Text] [Related]
11. Targeted monoclonal antibody therapy and radioimmunotherapy for lymphoproliferative disorders of the ocular adnexa.
Shome D; Esmaeli B
Curr Opin Ophthalmol; 2008 Sep; 19(5):414-21. PubMed ID: 18772675
[TBL] [Abstract][Full Text] [Related]
12. Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma.
Motta G; Cea M; Carbone F; Augusti V; Moran E; Patrone F; Nencioni A
J BUON; 2011; 16(1):9-15. PubMed ID: 21674844
[TBL] [Abstract][Full Text] [Related]
13. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma.
Buchegger F; Press OW; Delaloye AB; Ketterer N
Oncologist; 2008 Jun; 13(6):657-67. PubMed ID: 18586921
[TBL] [Abstract][Full Text] [Related]
14. Update on front-line therapy for follicular lymphoma: chemo-immunotherapy with rituximab and survival.
Turturro F
Expert Rev Anticancer Ther; 2007 Jul; 7(7):959-65. PubMed ID: 17627454
[TBL] [Abstract][Full Text] [Related]
15. Biology and treatment of Burkitt's lymphoma.
Yustein JT; Dang CV
Curr Opin Hematol; 2007 Jul; 14(4):375-81. PubMed ID: 17534164
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for HIV-associated non-Hodgkin's lymphoma.
Newsom-Davis T; Ahamed E; Bower M
Expert Opin Biol Ther; 2009 Oct; 9(10):1313-24. PubMed ID: 19645631
[TBL] [Abstract][Full Text] [Related]
18. Follicular lymphoma: time for a re-think?
Gandhi MK; Marcus RE
Blood Rev; 2005 May; 19(3):165-78. PubMed ID: 15748964
[TBL] [Abstract][Full Text] [Related]
19. Overview of non-Hodgkin's lymphoma: biology, staging, and treatment.
Fisher RI
Semin Oncol; 2003 Apr; 30(2 Suppl 4):3-9. PubMed ID: 12728402
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin's lymphoma following treatment with iodine-131-rituximab radio-immunotherapy.
Bishton MJ; Hicks RJ; Westerman DA; Prince MH; Wolf M; Seymour JF
Haematologica; 2008 May; 93(5):789-90. PubMed ID: 18450737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
